EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access

Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study

Huiqiang Huang iD, Rong Tao iD, Siguo Hao, Yu Yang, Hong Cen iD, Hui Zhou, Ye Guo, Liqun Zou, Junning Cao, Yunhong Huang, Jie Jin iD, Liling Zhang und 13 weitere

Journal of Clinical Oncology · 01.06.2023 · 41 (16) · 3032-3041

DOI: 10.1200/jco.22.02367 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.06.2023. Verfasst von Huiqiang Huang und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. Hauptthemen laut MEDLINE: Lymphoma, Extranodal NK-T-Cell. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) is a rare and aggressive type of non-Hodgkin lymphoma with limited treatment options. This phase II study evaluated the efficacy and safety of sugemalimab, an anti–PD-L1 monoclonal antibody, in R/R ENKTL. METHODS Eligible patients received sugemalimab 1,200 mg intravenously once every 3 weeks for up to 24 months or until progression, death, or study withdrawal. The primary end point was objective response rate (ORR) assessed by an independent radiologic review committee. Key secondary end points included ORR assessed by the investigators, complete response rate, duration of response, and safety. RESULTS At the data cutoff (February 23, 2022), 80 patients were enrolled and followed for a median of 18.7 months. At baseline, 54 (67.5%) had stage IV disease and 39 (48.8%) had received ≥2 lines of prior systemic therapy. Independent radiologic review committee–assessed ORR was 44.9% (95% CI, 33.6 to 56.6); 28 (35.9%) patients achieved a complete response and seven (9.0%) achieved a partial response, with a 12-month duration of response rate of 82.5% (95% CI, 62.0 to 92.6). Investigator-assessed ORR was 45.6% (95% CI, 34.3 to 57.2), and 24 (30.4%) patients achieved a complete response. Most treatment-emergent adverse events were grade 1-2 in severity, and grade ≥ 3 events were reported in 32 (40.0%) patients. CONCLUSION Sugemalimab showed robust and durable antitumor activity in R/R ENKTL. Treatment was well tolerated with expected safety profile for this drug class.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Extranodal NK-T-CellHumansTreatment OutcomeAntibodies, MonoclonalKiller Cells, NaturalAntibodies, Monoclonal, Humanized

Substanzen

Antibodies, MonoclonalsugemalimabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Department of Hematology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Lymphoma, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, China.
  • Department of Medical Oncology, Guangxi Cancer Hospital and of Guangxi Medical University Affiliated Cancer Hospital, Nanning, China.
  • Department of Lymphoma and Hematology, Hunan Cancer Hospital, Changsha, China.
  • Department of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.

ORCID-Profile: Huiqiang Huang, Rong Tao, Hong Cen, Jie Jin, Yanyan Liu

Zitieren

APA

Huang, H., Tao, R., Hao, S., Yang, Y., Cen, H., Zhou, H., Guo, Y., Zou, L., Cao, J., Huang, Y., Jin, J., Zhang, L., Yang, H., Xing, X., Zhang, H., Liu, Y., Ding, K., Qi, Q., Zhu, X., …, & Yang, J. (2023). Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study. Journal of Clinical Oncology, 41(16), 3032-3041. https://doi.org/10.1200/jco.22.02367

Vancouver

Huang H, Tao R, Hao S, Yang Y, Cen H, Zhou H, et al. Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study. Journal of Clinical Oncology. 2023;41(16):3032-3041. doi:10.1200/jco.22.02367

BibTeX
@article{Huang2023,
  author = {Huang, Huiqiang and Tao, Rong and Hao, Siguo and Yang, Yu and Cen, Hong and Zhou, Hui and Guo, Ye and Zou, Liqun and Cao, Junning and Huang, Yunhong and Jin, Jie and Zhang, Liling and Yang, Haiyan and Xing, Xiaojing and Zhang, Huilai and Liu, Yanyan and Ding, Kaiyang and Qi, Qinzhou and Zhu, Xiaoli and Zhu, Dan and Wang, Siyuan and Fang, Teng and Dai, Hangjun and Shi, Qingmei and Yang, Jason},
  title = {Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {16},
  pages = {3032--3041},
  doi = {10.1200/jco.22.02367}
}
Kostenlos starten →